BORTEZOMIB

Bortezomib (BORTINAT) is approved to treat:

  • Multiple myeloma.
  • Mantle cell lymphoma in patients who have already received at least one other type of treatment.

 

 BortezomibBORTENAT
AVAILABLE AS:
2 & 3.5 mg Ing (Single Dose Vial )
MANUFACTURE BY:
NATCO (INDIA)

Recommended Dose:

Adult Dose for Multiple Myeloma

For use in the treatment of previously untreated multiple myeloma:
Usual dose: 1.3 mg/m2 administered as a 3 to 5 second bolus IV injection or subcutaneously in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles.

In cycles 1 through 4, bortezomib is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32). In cycles 5 through 9, bortezomib is administered once weekly (days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of bortezomib.

For use in the treatment of relapsed multiple myeloma:
1.3 mg/m2 as a bolus intravenous injection or subcutaneously twice weekly for two weeks (days 1, 4, 8, and 11) followed by a ten day rest period (days 12 through 21)
The three week period is considered a treatment cycle.
A minimum of 72 hours should elapse between consecutive doses of bortezomib

Adult Dose for Mantle cell Lymphoma

1.3 mg/m2 as a bolus intravenous injection or subcutaneously twice weekly for two weeks (days 1, 4, 8, and 11) followed by a ten day rest period (days 12 through 21)
The three week period is considered a treatment cycle.
A minimum of 72 hours should elapse between consecutive doses of bortezomib


Please note
BORTINAT (Bortizomib ) is a prescription drug and should be only used under proper medical guidance and advice.
This medicine is to be taken strictly under Supervision of Medical Oncologist Only